CL2021003437A1 - Agonistas de il2 - Google Patents

Agonistas de il2

Info

Publication number
CL2021003437A1
CL2021003437A1 CL2021003437A CL2021003437A CL2021003437A1 CL 2021003437 A1 CL2021003437 A1 CL 2021003437A1 CL 2021003437 A CL2021003437 A CL 2021003437A CL 2021003437 A CL2021003437 A CL 2021003437A CL 2021003437 A1 CL2021003437 A1 CL 2021003437A1
Authority
CL
Chile
Prior art keywords
polynucleotides
polypeptides
human
host cells
functional variant
Prior art date
Application number
CL2021003437A
Other languages
English (en)
Inventor
Ugur Sahin
Sina Fellermeier-Kopf
Alexander Muik
Mathias Vormehr
Lena Mareen Kranz
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CL2021003437A1 publication Critical patent/CL2021003437A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

La invención se refiere a variantes de interleucina-2 (IL2). En particular, la invención se refiere a un polipéptido que comprende una muteína de IL2 humana o de una variante funcional de IL2 humana, en donde la IL2 humana o variante funcional de la misma se sustituye tal que se mejora la afinidad para el complejo del receptor βγ IL2 (IL2Rβγ). En una forma de realización, la IL2 humana o variante funcional de la misma se sustituye adicionalmente tal que se reduce la afinidad para el complejo del receptor de αβγ IL2 (IL2Rαβγ). En una forma de realización, el polipéptido activa las células T efectoras sobre las células T reguladoras. La invención también se refiere a polinucleótidos que codifican para los polipéptidos de la invención, células hospederas que comprenden los polinucleótidos, composición farmacéuticas que comprenden los polipéptidos, polinucleótidos o células hospederas, métodos terapéuticos o profilácticos de tratamiento utilizando los polipéptidos, polinucleótidos, células hospederas o composición farmacéuticas y preparaciones médicas que comprenden los polipéptidos, polinucleótidos, células hospederas o composición farmacéuticas.
CL2021003437A 2019-06-24 2021-12-21 Agonistas de il2 CL2021003437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2019066648 2019-06-24

Publications (1)

Publication Number Publication Date
CL2021003437A1 true CL2021003437A1 (es) 2022-09-23

Family

ID=71103401

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003437A CL2021003437A1 (es) 2019-06-24 2021-12-21 Agonistas de il2

Country Status (16)

Country Link
US (1) US20220356223A1 (es)
EP (1) EP3986916A1 (es)
JP (1) JP2022539543A (es)
KR (1) KR20220027864A (es)
CN (1) CN114450296A (es)
AR (1) AR119231A1 (es)
AU (1) AU2020308592A1 (es)
BR (1) BR112021026147A2 (es)
CA (1) CA3142911A1 (es)
CL (1) CL2021003437A1 (es)
CO (1) CO2021017639A2 (es)
CU (1) CU20210105A7 (es)
IL (1) IL288536A (es)
MX (1) MX2021015852A (es)
TW (1) TW202115105A (es)
WO (1) WO2020260270A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20220020A7 (es) 2022-03-18 2023-12-07 Ct Inmunologia Molecular Muteínas derivadas de la interleucina-2 humana con actividad superagonista
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN102584997A (zh) 2002-11-08 2012-07-18 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン．ヴェー． 半減期の長い血清アルブミン結合タンパク質
CN101965198A (zh) 2007-12-27 2011-02-02 诺瓦提斯公司 改进的基于纤连蛋白的结合分子及其用途
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
BR112012026216B1 (pt) 2010-04-13 2022-07-26 Bristol-Myers Squibb Company Proteínas com domínio "scaffold" baseado em fibronectina que se ligam à pcsk9, seu uso, bem como composição farmacêutica compreendendo as mesmas
AU2012215573B2 (en) * 2011-02-10 2015-11-26 Roche Glycart Ag Mutant interleukin-2 polypeptides
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
BR112021000811A8 (pt) * 2018-07-24 2022-10-18 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Agonistas de il2

Also Published As

Publication number Publication date
CA3142911A1 (en) 2020-12-30
CU20210105A7 (es) 2022-08-09
CO2021017639A2 (es) 2022-01-17
MX2021015852A (es) 2022-02-03
TW202115105A (zh) 2021-04-16
IL288536A (en) 2022-01-01
AR119231A1 (es) 2021-12-01
WO2020260270A1 (en) 2020-12-30
EP3986916A1 (en) 2022-04-27
JP2022539543A (ja) 2022-09-12
US20220356223A1 (en) 2022-11-10
AU2020308592A1 (en) 2022-01-06
BR112021026147A2 (pt) 2022-05-10
KR20220027864A (ko) 2022-03-08
CN114450296A (zh) 2022-05-06

Similar Documents

Publication Publication Date Title
BR112021000811A8 (pt) Agonistas de il2
CO2021017639A2 (es) Agonistas de il2
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112018016281A2 (pt) molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
PE20140303A1 (es) Polipeptidos interleuquina-2 mutantes
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
JP2017513503A5 (es)
PE20150648A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
EA202192555A1 (ru) Комбинированная терапия для лечения рака
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
BR112021021284A2 (pt) Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra
BR112019023260A2 (pt) Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos
WO2021222150A3 (en) Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CO2021000210A2 (es) Apirasas solubilizadas, métodos y usos
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
MX2022000713A (es) Derivados de bencenosulfonamida y usos de las mismas.
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
BR112017022390A2 (pt) composição farmacêutica
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
BR112023000229A2 (pt) Composto, composição farmacêutica, e, peptídeo